- Ab01036-10.0 Anti-NS1 [ZKA35]
- Zika Virus
- Human IgG1
- HRP conjugate, Purified
- In Stock
Recombinant monoclonal antibody to NS1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the B-cell clone ZKA35.
Alternative Name(s) of Target: non-structural protein 1; non structural protein 1; ZIKV NS-1
Immunogen: Antibody ZKA35 was isolated from peripheral blood mononuclear cell (PBMC) and blood plasma collected from a ZIKV-infected patient.
Specificity: This antibody binds to the Zika virus NS1 protein at a site not targeted by antibodies cross-reactive with Dengue virus (DENV1 -4) or other flaviviruses such as West Nile Virus or Yellow Fever Virus.
Application Notes: This antibody can be used to specifically detect Zika virus as it is not cross-reactive with other flaviviridae. Balmaseda and coworkers (PMID: 28716913) used this antibody to develop a blockade-of-binding (BOB) assay able to discriminate immune responses to Zika infection from infections by other flaviviruses. In this assay, binding of ZKA35 to an NS1-antigen coated plate is blocked by Zika-specific antibodies found in positive patient serum, whilst sera from patients infected with other flaviviruses will be unable to do so as they do not contain competitive antibodies. This assay is an alternative it RT-PCR based methods, which suffer from a narrow time window during which viral RNA is detectable in bodily fluids. We exclusively offer this antibody as a horseradish peroxidase (HRP) conjugate for easy use in BOB ELISA assays (Ab01036-10.0-BOB). ZKA25 (human IgG1, Ab01006-10.0) can be used as a positive as a positive control. At a concentration of 5 ug/ml of ZKA25 (Ab01006-10.0), full blockade of binding (i.e. partial-competitive inhibition of ZKA35 binding) can be achieved, though more reliable blockade is achieved by homologous blockade. We therefore offer this HRP-conjugated antibody alongside a 40 ug vial of unconjugated control. Please refer to Ab01036-10.0-BOC or individually as Ab01036-10.0-CTL. A suggested protocol can be found here. Please refer to Balmaseda et al. 2018 (PMID: 29305550 ) for further examples of the use of this antibody and its positive control.
Antibody first published in:
Balmaseda et al. Antibody-based assay discriminates Zika virus infection from other flaviviruses Proc Natl Acad Sci U S A. 2017 Aug 1;114(31) PMID:28716913
Note on publication: Describes the development of the BOB-ELISA assay and characterisation of the specificity of this assay for Zika virus infection.